Literature DB >> 29554237

Real-life characteristics and outcomes of patients who undergo percutaneous coronary intervention versus coronary artery bypass grafting for left main coronary artery disease: data from the prospective Multi-vessel Coronary Artery Disease (MULTICAD) Israeli Registry.

Eilon Ram1, Ilan Goldenberg2, Yigal Kassif1, Amit Segev2, Jacob Lavee1, Michal Einhorn-Cohen2, Ehud Raanani1.   

Abstract

OBJECTIVES: Left main coronary artery involvement in patients with multivessel coronary artery disease provides a poor prognosis. Although the main strategy for revascularization is by coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) is being used with increased frequency.
METHODS: This prospective, 3-year follow-up study included 1063 consecutive patients with multivessel coronary artery disease enrolled between January and April 2013 from all 22 hospitals in Israel that perform coronary angiography and PCI.
RESULTS: Of the 1063 patients, 252 (24%) had left main coronary artery disease. Of them, 27% were treated by PCI and 73% by CABG. Factors associated with referral for PCI included older age [odds ratio (OR) 1.04; P = 0.021], renal impairment (OR 3.52; P = 0.006), prior PCI (OR 2.23; P = 0.041) and lower SYNTAX score (OR 1.05; P = 0.004). Kaplan-Meier survival analysis showed that after 3 years, all-cause mortality among left main coronary artery disease patients was significantly higher among those who underwent PCI versus CABG (26.9% vs 8.7%; P < 0.001). Multivariable analysis showed that PCI was associated with a >2-fold increased hazard for mortality compared with surgical revascularization (hazard ratio 2.13, 95% confidence interval 1.05-4.31; P = 0.036).
CONCLUSIONS: In real-life practice, clinical factors and a lower SYNTAX score affect the decision to perform PCI in left main coronary artery disease patients. Our findings suggest that CABG is associated with improved long-term survival compared to PCI in patients with left main coronary artery disease after adjustment for those factors.

Entities:  

Mesh:

Year:  2018        PMID: 29554237     DOI: 10.1093/ejcts/ezy115

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

Review 1.  Cardiac surgery 2018 reviewed.

Authors:  Torsten Doenst; Steffen Bargenda; Hristo Kirov; Alexandros Moschovas; Sophie Tkebuchava; Rauf Safarov; Mahmoud Diab; Gloria Faerber
Journal:  Clin Res Cardiol       Date:  2019-03-30       Impact factor: 5.460

Review 2.  The Current State of Coronary Revascularization: Percutaneous Coronary Intervention versus Coronary Artery Bypass Graft Surgery.

Authors:  Matthew A Brown; Seth Klusewitz; John Elefteriades; Lindsey Prescher
Journal:  Int J Angiol       Date:  2021-11-10

3.  Intravenous injection of extracellular vesicles to treat chronic myocardial ischemia.

Authors:  Laura A Scrimgeour; Brittany A Potz; Ahmad Aboul Gheit; Yuhong Liu; Guangbin Shi; Melissa Pfeiffer; Bonnie J Colantuono; Neel R Sodha; M Ruhul Abid; Frank W Sellke
Journal:  PLoS One       Date:  2020-09-11       Impact factor: 3.240

4.  Safety and efficacy of percutaneous coronary intervention versus coronary artery bypass graft in patients with STEMI and unprotected left main stem disease: A systematic review & meta-analysis.

Authors:  Talal Almas; Ahson Afzal; Hameeda Fatima; Sadia Yaqoob; Furqan Ahmad Jarullah; Zaeem Ahmed Abbasi; Anoosh Farooqui; Duaa Jaffar; Atiya Batool; Shayan Ahmed; Neha Sara Azmat; Fatima Afzal; Sarah Zafar Khan; Kaneez Fatima
Journal:  Int J Cardiol Heart Vasc       Date:  2022-04-25

5.  Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China.

Authors:  Xueyan Zhao; Lianjun Xu; Lin Jiang; Jian Tian; Yin Zhang; Dong Wang; Kai Sun; Bo Xu; Wei Zhao; Rutai Hui; Runlin Gao; Lei Song; Jinqing Yuan
Journal:  Cardiovasc Diabetol       Date:  2021-01-11       Impact factor: 9.951

6.  The predictive value of creatinine clearance for mortality in patients undergoing revascularization.

Authors:  Eilon Ram; Pazit Beckerman; Amit Segev; Nir Shlomo; Abigail Atlas-Lazar; Leonid Sternik; Ehud Raanani
Journal:  J Cardiothorac Surg       Date:  2021-05-01       Impact factor: 1.522

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.